Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 HCV infection: an open-label, phase 3 trial.
Omata M, Nishiguchi S, Ueno Y, Mochizuki H, Izumi N, Ikeda F, Toyoda H, Yokosuka O, Nirei K, Genda T, Umemura T, Takehara T, Sakamoto N, Nishigaki Y, Nakane K, Toda N, Ide T, Yanase M, Hino K, Gao B, Garrison KL, Dvory-Sobol H, Ishizaki A, Omote M, Brainard D, Knox S, Symonds WT, McHutchison JG, Yatsuhashi H, Mizokami M. Omata M, et al. Among authors: garrison kl. J Viral Hepat. 2014 Nov;21(11):762-8. doi: 10.1111/jvh.12312. Epub 2014 Sep 8. J Viral Hepat. 2014. PMID: 25196837 Clinical Trial.
A phase IIIb study of ledipasvir/sofosbuvir fixed-dose combination tablet in treatment-naïve and treatment-experienced Korean patients chronically infected with genotype 1 hepatitis C virus.
Lim YS, Ahn SH, Lee KS, Paik SW, Lee YJ, Jeong SH, Kim JH, Yoon SK, Yim HJ, Tak WY, Han SY, Yang JC, Mo H, Garrison KL, Gao B, Knox SJ, Pang PS, Kim YJ, Byun KS, Kim YS, Heo J, Han KH. Lim YS, et al. Among authors: garrison kl. Hepatol Int. 2016 Nov;10(6):947-955. doi: 10.1007/s12072-016-9726-5. Epub 2016 May 20. Hepatol Int. 2016. PMID: 27198664 Clinical Trial.
Safety and Efficacy of Ledipasvir-Sofosbuvir With or Without Ribavirin for Chronic Hepatitis C in Children Ages 6-11.
Murray KF, Balistreri WF, Bansal S, Whitworth S, Evans HM, Gonzalez-Peralta RP, Wen J, Massetto B, Kersey K, Shao J, Garrison KL, Parhy B, Brainard DM, Arnon R, Gillis LA, Jonas MM, Lin CH, Narkewicz MR, Schwarz K, Rosenthal P. Murray KF, et al. Among authors: garrison kl. Hepatology. 2018 Dec;68(6):2158-2166. doi: 10.1002/hep.30123. Epub 2018 Nov 17. Hepatology. 2018. PMID: 30070726 Clinical Trial.
The oral toll-like receptor-7 agonist GS-9620 in patients with chronic hepatitis B virus infection.
Gane EJ, Lim YS, Gordon SC, Visvanathan K, Sicard E, Fedorak RN, Roberts S, Massetto B, Ye Z, Pflanz S, Garrison KL, Gaggar A, Mani Subramanian G, McHutchison JG, Kottilil S, Freilich B, Coffin CS, Cheng W, Kim YJ. Gane EJ, et al. Among authors: garrison kl. J Hepatol. 2015 Aug;63(2):320-8. doi: 10.1016/j.jhep.2015.02.037. Epub 2015 Feb 27. J Hepatol. 2015. PMID: 25733157 Clinical Trial.
Organic Anion Transporting Polypeptide Inhibition Dramatically Increases Plasma Exposure but not Pharmacodynamic Effect nor Inferred Hepatic Intracellular Exposure of Firsocostat.
Kirby BJ, Lutz JD, Yue MS, Garrison KL, Qin AR, Ampaw L, Beysen C, Myers RP, Kearney BP, Mathias A. Kirby BJ, et al. Among authors: garrison kl. Clin Pharmacol Ther. 2021 May;109(5):1334-1341. doi: 10.1002/cpt.2105. Epub 2020 Nov 25. Clin Pharmacol Ther. 2021. PMID: 33141923 Clinical Trial.
Using implementation science to evaluate a population-wide genomic screening program: Findings from the first 20,000 In Our DNA SC participants.
Allen CG, Hunt KJ, McMahon LL, Thornhill C, Jackson A, Clark JT, Kirchoff K, Garrison KL, Foil K, Malphrus L, Norman S, Ramos PS, Perritt K, Brown C, Lenert L, Judge DP. Allen CG, et al. Among authors: garrison kl. Am J Hum Genet. 2024 Mar 7;111(3):433-444. doi: 10.1016/j.ajhg.2024.01.004. Epub 2024 Feb 1. Am J Hum Genet. 2024. PMID: 38307026
15 results